510(k) Guidance Footnote May Signal Greater FDA Oversight Of Preclinical Testing
This article was originally published in The Gray Sheet
Executive Summary
Device industry experts say a seemingly minor footnote to the recent 510(k) program draft guidance could create a new requirement for nonclinical studies.